CCM
SPRB

CAAS Capital Management’s Spruce Biosciences SPRB Stock Holding History

CAAS Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-367
Closed -$166K – 1083
2021
Q3 		$166K Sell
367
-865
-70% -$543K ﹤0.01% 752
2021
Q2 		$1.04M Buy
+1,232
New +$1.31M 0.02% 535
2021
Q1 		– Sell
-133
Closed -$243K – 1443
2020
Q4 		$243K Buy
+133
New +$220K ﹤0.01% 750

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's SPRB Position: Q4 2021 in Review

CAAS Capital Management sold out of Spruce Biosciences (SPRB) in Q4 2021, closing a stake of 367 shares — an estimated $166K sold.

CAAS Capital Management first reported a position in SPRB in Q4 2020 and held it in 3 quarters. The position peaked at $1.04M in Q2 2021. 50 funds tracked by Wall St. Rank hold SPRB as of Q4 2021.

  • CAAS Capital Management reported no remaining Spruce Biosciences position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 367 Spruce Biosciences shares in Q4 2021, an estimated $166K.
  • CAAS Capital Management first reported a position in Spruce Biosciences in Q4 2020 and held it in 3 quarters.
  • CAAS Capital Management's Spruce Biosciences position peaked at $1.04M in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.